gh strongli posit market leader liquid biopsi comprehens genet
profil cancer patient trust partner grow number major
biopharma partner addit gh attract product pipelin target larg
markets/area need recurr monitor asymptomat test
initi outperform rate price target
gh establish market leader comprehens genet profil cancer
patient use blood vs tissu gh initi focu non-smal cell lung cancer
nsclc pathway compani assay use
across cancer well valid via patient complet studi
peer-review public studi on-going nsclc studi on-going
cancer gh disciplin thorough effort establish clinic util
posit compani well reimburs regulatori purpos posit
local coverag decis nsclc grant summer fda approv
correspond nation coverag decis potenti pan-canc expect within
next month
approxim american diagnos advanc metastat cancer
year comprehens genet profil patient help optim therapi
select genet profil done typic done use tissu sampl blood
solid tumor unfortun challeng approach includ
insuffici tissu estim lung cancer accord studi
access patient test recommend action biomark
 inconsist analysi cancer commun variou level
patholog sophist long turn-around time studi indic patient
get egfr alon result week post diagnosi
gh requir littl sampl vial provid answer quickli
day averag comprehens gene includ nccn guidelin recommend
gene well valid see gain steam payer see
like alreadi order oncologist adopt
global biopharma oncolog pipelin biomark depend
ongoing/enrol combin clinic studi involv patient
studi need assay like help biopharma develop identifi target profil
therapeut design studi optim combin decis recruit patient gh
alreadi partner biopharma compani includ azn bm
name addit gh launch guardantomni much
content includ tmb biomarker-driven pharma develop assay
assay develop azn bm other note omni asp
higher
continu page
pleas see page report import disclosur
comprehens genom profil gain market accept due recent develop
fda approv cdx coverag decis biomark expand
clinic trial diversifi need test broader panel believ gh liquid
biopsi panel well-posit take advantag shift could outpac tissue-
base competitor due advantag blood-bas profil guardant strong
support data led adopt half oncologist us
inclus nccn cancer center compani submit fda approv
believ lead broaden nation coverag decis subsequ
commerci payer decis guardant also work top biopharma
help drive clinic trial success cdx develop final signific upsid
lunar program could potenti target larg patient popul
fda submiss earli
fda/cm decis late
nation coverag implement
reimburs rate
increas
privat payer coverag remain flat
near term due lengthi coverag
clinic biopharma test volum
grow y/i
mileston reach biopharma
clinic biopharma volum grow
materi driven coverag
reimburs quicker broader
expect new commerci contract
pharma revenu increas materi
new partnership establish
y/i due limit perceiv util
privat reimburs gh test
revenu come later expect
biopharma program take longer
expect implement yield minim
gh molecular diagnost compani found
provid comprehens genom profil servic clinic
biopharma custom guardant deriv revenu sell product enabl
compani molecular inform platform physician diagnost test
biopharmaceut compani diagnost test databas driven servic guardant
launch liquid biopsi blood test guardantomni advanc
stage cancer compani also program underway develop
test recurr earli stage cancer detect respect test primarili run
guardant headquart redwood citi california test run
custom site md anderson test also use biopharma compani
clinic trial enrol drug develop commerci post-approv
guardant biopharma partner
next year expect gh gain fda approv broad reimburs
rapidli expand commerci coverag spite
penetr address market lung outsid lung
forecast penetr clearli leav room upsid addit
also room clinic upsid ou manag enthus outlook addit
sourc biopharmaceut revenu beyond captur forecast final
note compani promis pipelin product huge market
recurr monitor asymptomat screen lunar lunar repres
clear sourc potenti upsid forecast time
gh strongli posit market leader liquid biopsi comprehens genet
profil cancer patient also trust partner grow number major
biopharmaceut partner addit attract product pipelin target
larg markets/area need recurr monitor asymptomat test
clearli attract profil gh degre captur surfac pretti
robust valuat said believ price target support appli
nomin premium peer multipl test revenu valu gh test
databas level appli fmi earlier year grant compani
pipelin valu
gh molecular diagnost compani found
provid comprehens genom profil servic clinic
biopharma custom guardant deriv revenu sell product enabl
compani molecular inform platform physician diagnost test
biopharmaceut compani diagnost test databas driven servic guardant
launch liquid biopsi blood test guardantomni advanc
stage cancer compani also program underway
develop test recurr earli stage cancer detect respect test
primarili run guardant headquart redwood citi california test
run custom site md anderson test also use
biopharma compani clinic trial enrol drug develop
commerci post-approv guardant biopharma partner
comprehens genom profil start gain broader market accept due
recent develop fda approv companion diagnost
number clinic trial diversifi clear need test patient
broader panel hotspot test believ guardant gene
marker liquid biopsi panel well-posit take advantag market shift
could outpac tissue-bas competitor advantag tissue-bas
profil includ liquid biopsi eas use cost lack sampl limit abil
comprehens detect entir tumor addit believ guardant test
differenti rel liquid biopsi peer guardant rigor
shown test concord tissu base approach influenc
clinician treatment decis compani boast peer-review public
clinic outcom studi total led adopt half
oncologist practic us today inclus nccn cancer center insur
start cover test well guardant local medicar contractor began
cover test octob compani plan submit fda
approv believ lead broaden nation medicar
coverag decis subsequ commerci payer decis test also
well adopt biopharma partner guardant current work
top pharma biotech guardant help drive clinic trial enrol
analysi patient sampl uncov new genet insight companion diagnost
develop futur approv therapi final feel signific upsid
lunar program could potenti target larg patient
appli in-line-with-p sale multipl project test revenu
forecast translat combin databas valu
attribut lunar program support valuat target
outperform rate
clinic opportun genet profil larg current late
stage cancer patient diagnos year consid sever target io
therapi avail patient popul comprehens genet profil
high clinic util set help determin precis medicin
would like effect base underli gene mutat patient
tumor despit clear use case market vastli under-penetrated
late stage metastat cancer patient undergo broad genet test
nsclc patient test nccn recommend action biomark
believ guardant well-posit drive penetr within market
well-valid high qualiti test drive broader physician awar
gain regulatori approv reimburs coverag
integr therapeut via companion diagnost develop
tissue-bas profil current standard approach molecular cancer
diagnost sever shortcom limit tissue-bas profil includ
invas associ complic reliant suffici tissu
avail high site-to-sit intra-tumor variabl slow
consid collect tissu biopsi often requir lengthi schedul
coordin effort among specialist costli advantag liquid biopsi
includ non-invas inexpens consid requir
surgeri tissu depend enabl serial monitor potenti
applic recurr monitor resist monitor even earli
detect quick routin conveni could especi help
commun set comprehens sinc provid inform entir
tumor system specif region tumor
recent grant posit coverag decis local medicar
contractor late stage nsclc patient favor reimburs rate
although privat reimburs current limit hand
blue believ could continu improv view driven fact
grant breakthrough devic design fda offer
potenti expedit path fda approv guardant plan submit fda
earli anticip decis late believ posit decis
fda would valid guardant test could help expand privat
guardant one first compani offer comprehens genom profil cgp
circul tumor dna provid compani meaning first
mover advantag key differenti clinic end market
difficult chang custom order pattern he/sh find product
work well sticki strong data support peer review public
clinic outcom studi includ largest liquid-to-tissu concord
studi sever prospect studi believ support data driven
adopt test current use oncologist us
order nccn cancer center
test perform believ guardant share
clinic liquid biopsi market expect guardant clinic volum grow
compound-annual-growth-rate next year believ strong upward bia model
clinic regulatori reimburs progress combin marketing-driven
increas awar bode well fmi volum outlook
success person medicin caus definit shift way cancer
patient treat today shift creat increas number
biopharma program clinic trial target therapeut turn
creat need tool comprehens profil patient offer
guardant evidenc fact guardant test alreadi well
adopt biopharma commun guardant broader panel guardantomni
increasingli order custom well guardant current work
top pharma biotech includ biopharma compani
contract discuss notabl partner includ astrazeneca novarti
roch lilli johnson johnson bayer expect
biopharma collabor continu increas deepen base compel
attribut guardant biopharma product portfolio
also believ competitor valu guardant continu expand databas
cancer patient excess patient today recent
sever acquisit databas compani biopharma lucr databas access
agreement believ clear demonstr valu biopharma
note compani promis pipelin product huge
market recurr monitor asymptomat screen lunar
repres clear sourc potenti upsid forecast time compani
plan releas soon biopharma partner announc
promis earli date project could repres
much address patient opportun respect
list price guardant comprehens genom profil test
highli reliant insur coverag rather patient pay clinic revenu
far commerci reimburs decis guidelin inclus slow
materi current cover late stage lung cancer patient
insuffici tissu medicar hand blue nccn guidelin
said note payer recent issu decis cover
comprehens genom profil coverag decis liquid biopsi even
nascent therefor believ first inning momentum
acceler payer commun addit believ posit fda outcom
next year could catalyz payer coverag within lung well cancer
type stage
mani part run genet test somat cancer becom somewhat
commodit exampl major lab use sequenc consum
gener sequenc result furthermor ip protect much limit
cost sequenc come dramat year enabl place
lower capit budget also becom involv genet test
barrier entri somewhat lower like competit
landscap becom crowd reimburs comprehens
current estim indic gene action cancer
action gene mutat detect patient tumor unclear
drive cancer pathogenesi particular patient nois
also note practic benefit sever biomark guardant test like
fulli realiz yet word drug discoveri develop kept
pace biolog inform guardant test provid
improv time consid increas interest gene-diseas associ
new studi gener biopharma past sever year
current forecast guardant end cash
balanc sheet seem like hefti sum emerg compani
forecast oper cash burn alon
forecast ebitda profit therefor possibl compani
need rais addit fund futur although
compar compani analysi includ blend specialti lab compani
genom high growth med-tech peer
nanostr edward genmark compar group current
trade blend mean ev/sal multipl guardant current
valu premium peer group mean ev/sal basi
therefor support current valuat use tradit methodolog arguabl
requir look ahead sever year believ revenu forecast
support bottoms-up market analysi believ notabl
upsid potenti materi amount risk revenu ramp outlook
trajectori therefor valuat risk said believ worth note
gh expect gener sale growth greater almost everi compar
compani justifi premium rel valuat believ
sever sourc larg unmodel upsid lunar program biopharma
signific need genom profil cancer accord seer
databas patient diagnos cancer year us
initi sign cancer may detect number physician final diagnosi
often perform oncologist follow thorough screen
oncologist practic us may seem like larg number
oncologist see patient per day averag consequ
oncologist increasingli busi schedul less time spend review
literatur new treatment option believ especi true
commun set doctor potenti distanc academ
research provid overal cancer patient care even commun doctor
made time follow oncolog develop would like difficult keep
date complet current immuno-oncolog program
heighten need genom profil late stage cancer need due
fact metastat prolif natur late cancer make
ineffect treat patient base sole tumor primari locat instead
clinician target cancer system share mutat profil
hope erad slow growth throughout entir bodi base recent
seer data patient us diagnos advanc cancer per year
metastat stage iiib/iv patient
clear need perform genom profil late stage cancer
grow number divers target therapi creat need genom
profil quit broad particularli import cancer multipl
biomark associ therapeut shown nccn guidelin
recommend test differ genom alter advanc cancer type
illustr need comprehens genom profil approach set
howev still perform practic accord recent report
late stage metastat cancer patient undergo broad genet test
nsclc patient test nccn recommend action
figur percentag nsclc patient test nccn recommend
cowen compani
precis oncolog cancer patient match person treatment base
underli molecular profil patient tumor tradit method
analyz patient tumor involv collect sampl patient tumor biopsi
surgeri howev method sever limit note
invas potenti complic tissu biopsi
invas depend cancer type could also signific
morbid mortal studi investig lung biopsi exampl
note complic rate
insuffici tissu studi indic lung cancer
isnt enough tissu avail biopsi addit tissu biopsi may
option patient due patient unwilling logist
high variabl tissu patholog vari significantli site site
like attribut part due tissu biopsi limit small portion
heterogen tumor well vari level physician expertis
poor guidelin adher nsclc patient test
nccn recommend action biomark
slow collect tissu biopsi often requir medic imag procedur
locat cancer coordin amongst intervent radiologist
surgic oncologist pathologist interpret imag collect
analyz tissu tradit tissu biopsi take sever week
schedul addit time process sampl recent data indic
take week post-diagnosi patient get egfr result
costli averag total cost lung biopsi due larg
requir imag biopsi surgic procedur obtain tissu
overcom limit tradit tissu test commun increasingli
turn altern sourc sampl like liquid biopsi liquid biopsi test detect
circul biomark peripher blood screen cancer monitor tumor
statu recurr cancer patient believ liquid biopsi overcom mani
limit tradit test sinc follow attribut
non-invas inexpens unlik tissu test requir biopsi
surgeri liquid biopsi requir small blood sampl minim
risk complic obtain tumor sampl make less
expens tissu biopsi
tissu depend sinc liquid biopsi test requir tissu
especi valuabl case limit amount tissu
clinician take sever sampl cours treatment follow-up
visit could allow physician monitor patient real-tim
make adjust need
quick routin conveni could especi help
commun set cancer care take place
expertis access tissu biopsi may limit
comprehens unlik tissu test limit provid inform
area biopsi came liquid biopsi assess entir tumor
environ
background liquid biopsi pleas see liquid biopsi ahead curv
link note
guardant current two commerci test guardantomni
well addit test develop via program
launch molecular diagnost inform
therapi may effect late stage cancer patient solid tumor test
use first-lin therapi molecular test incomplet
unobtain limit progress avoid invas biopsi look
new genom target
liquid biopsi test requir ml blood test result
report within day sampl receipt clinic report includ somat
mutat detect associ treatment option avail clinic trial
vicin patient locat via guardantconnect list price
test specif design detect major type mutat
insert delet use digit next gener sequenc panel
design detect mutat cancer-rel gene includ nccn
octob panel augment includ microsatellit instabl
genet abnorm caus abund microsatellit repeat
mismatch repair gene prevent mismatch repair gene function
normal therefor imped dna repair may fda grant approv
merck immunotherapi drug keytruda patient solid tumor high
microsatellit instabl approv mark first cancer drug base
tumor genet profil rather locat bodi believ tumor
agnost indic repres paradigm shift therapi evalu
reinforc valu comprehens genet test analyz among
genet mutat
import liquid biopsi test high perform sensit
specif presenc ctdna blood low difficult
detect specif median concentr ctdna genom alter
blood earli stage advanc cancer patient respect
sensit rel level ctdna patient circul
detect reliabl lower instanc see fig
unlik tissu biopsi blood draw captur cell shed entir bodi
therefor import test result also specif area interest
specif depend mutat type
abl achiev high perform due guardant proprietari guardant
effici sampl prepar next gener sequenc bioinformat
pipelin serv dramat reduc error rate machin learn allow
perform improv guardant receiv new blood sampl
workflow highli accur transfer guardant deploy
platform md anderson test run in-hous
although sever commerci pipelin product comprehens
profil space remain scarciti compani done robust amount
clinic valid work guardant hand gener extens
backbon clinic data support assay includ peer-review
public scientif abstract guardant also complet
on-going nsclc studi studi gastrointestin cancer anoth studi
cancer type colorect breast compani indic also
invest studi earlier stage diseas
total guardant gener clinic outcom studi includ concord
studi valid studi prospect studi
concord valid studi april research publish extens
valid studi clinic cancer research link encompass consecut
clinic sampl make largest liquid tissu concord studi studi
indic posit predict valu rang depend
mutat time research assess genet profil
consecut sampl found detect rate ctdna high
action fda-approv on-label treatment option
treatment trial recommend
conduct cours year research determin
respons rate use assay line tissu biopsi approach
second clinic util studi publish octob jama oncolog link
demonstr almost doubl number target mutat found
tissu genotyp alon
liquid biopsi includ major us medic guidelin cancer treatment
guidelin bodi includ nccn repeat biopsi feasibl plasma biopsi
consid cap clinic set tissu limit and/or
insuffici molecular test physician may use cell-fre plasma dna
even patient abl undergo tradit tissu biopsi liquid
biopsi may safer quicker conveni perhap even
inform believ guidelin support may continu expand broaden
support data build even
believ extens valid inclus liquid biopsi guidelin
key drive strong adopt test thu far today like
market leader liquid biopsi test share market test
order oncologist oncologist us adopt
nation comprehens cancer network nccn cancer center
nation cancer institut nci site compani also strong academ
partnership key center md anderson run local
cumul test use time oncologist expect
guardant run test believ import note
would still repres less penetr market therefor believ
compani long runway growth ahead
regulatori reimburs statu improv
like first comprehens liquid biopsi test approv new york
state depart nysdoh guardant also seek fda approv
test grant expedit access pathway mention
fda approv would import develop regulatori landscap
molecular diagnost seem shift ldt fda-approv test
increas need fda-back test
coverag live us today includ coverag
hand privat payer includ refer medicar
repres us test process guardant privat payer
repres remain
juli palmetto gba respons administ medicar
molecular diagnost servic program issu local coverag decis lcd
stage iiib iv nsclc patient meet certain clinic criteria
case untreat patient diagnosi lcd state use
result egfr singl nucleotid variant snv insert delet indel
rearrang snv braf avail
tissue-bas cgp infeas quantiti suffici tissue-bas cgp
invas biopsi medic contraind
case treat patient progress use patient
progress chemotherapi immunotherapi never test
egfr snv indel rearrang snv braf
tissue-bas cgp infeas quantiti suffici tissue-bas
cgp origin biopsi patient progress tyrosin kinas inhibitor
septemb noridian respons adjud claim california
gh sampl process price lcd code
unlist molecular patholog procedur effect date octob
link decis indic guardant recent abl
receiv reimburs test
januari fda grant expedit access pathway
design offer potenti faster review breakthrough medic devic
address unmet medic need guardant plan submit pma applic
fda
march publish decis memorandum next-gener sequenc
test decis memorandum patient advanc cancer meet
certain clinic criteria decis memorandum state among thing
coverag would avail next-gener sequenc fda-approv test
offer within fda-approv companion vitro diagnost test label therefor
receiv fda approv believ also receiv ncd
base decis memorandum
compani expect fda-approv pan-canc coverag ncd
believ joint fda approv ncd coverag would valid
test place distinct advantag rel test
back
remain guardant us clinic volum patient privat
insur current hand payer cover test includ
alabama north carolina plan specif cover non-smal cell
lung cancer nsclc clinic volum believ lack
reimburs key barrier adopt although would
note guardant somewhat success bill network payer
believ guardant abl collect reimburs privat payer
volum said believ fda approv could catalyz meaning
sever compani perform tissue-bas genet test somat
cancer compani offer test directli compar guardant would
note differenti due panel content guardant
largest panel suprem court nullifi patent gene rather
guardant differenti platform precis effici well scale
broadli competit space genet profil somat cancer includ
provid hotspot cancer assay comprehens assay liquid biopsi test
competitor give test away free gain market share
gene much genet test solid tissu done today use hotspot
small panel similarli reimburs code develop individu
genet mutat howev hotspot test shown high fals
neg rate breadth precis therapi avail sinc highli target
therefor miss mani mutat compani number variat short insert
delet recent studi indic patient neg hotspot test
result actual detect genom alter link target
therapi anoth patient test neg hotspot
mutat genom alter clinic trial could consid
competitor hotspot small gene panel includ refer lab
labcorp quest tool compani specialti lab also
academ medic center develop in-hous hotspot test small
gene compani offer panel larger gene
compani develop platform includ thermo fisher
sinc mani compani quit larg reason expect
leverag infrastructur capabl fda success pursu
multipl strategi within grow attract field exampl
releas gene tumor panel develop variou sequenc
could take oncolog panel fda pathway miseq dx
instrument alreadi receiv fda approv
gene compani sever hundr gene panel includ foundat
medicin acquir roch nanthealth cari life scienc genom
foundat medicin foundationon cdx assay gene assay also
interrog tumor mutat burden tmb describ detail later earli
grant nation coverag decis fda approv
part parallel review pathway fmi ran foundationon test
track run test y/i
test besid receiv fast track equival fda
design foundat medicin foundationon liquid genom
diagnost elio plasma resolv differ similar note
less day
gene
submit
reimburs statu reimburs cover
live late stage nsclc
compani report cowen compani
foundat medicin acquir roch june
less week
gene
btmb expect fda test
gene
drug develop well known carri massiv financi time invest
well histor high failur rate take averag year
success navig clinic trial pathway fda websit cost
averag develop win market approv new drug tuft csdd
percent cancer drug termin phase ii
respect huber doyl massiv cost time develop
new drug low histor success rate creat need effici drug
start movement design drug tailor certain patient popul
order select patient respond particularli well smaller clinic trial
size cost first target drug approv herceptin
proport target therapi base genet mutat acceler ever
sinc today drug cancer drug base dna accord
tuft person medicin coalit mit review solid
tumor oncolog pipelin target therapi immuno-oncolog io
agent accord globaldata
find best respond immun therapi typic expens often
work major patient accordingli import determin via
genet profil patient toler respond well expens drug
reimburs regulatori purpos today seemingli
immuno-oncolog io target therapi trial underway mani
therapi target cancer base cancer specif molecular profil
therefor biopharmaceut compani increasingli invest genet profil
part drug develop pathway
decreas clinic trial cost accord research scripp institut
number patient would need conduct pivot clinic trial could
smaller biomark avail schork topol estim
phase phase ii phase clinic trial includ
use biomark oncolog vastli uniqu biomark target
indic audett
fda websit huber doyl cowen compani
address need guardant provid follow servic biopharma
partner earli stage research clinic develop commerci
improv clinic trial design patient select includ prospect screen
patient identifi best candid enrol clinic trial referr
clinic patient acceler clinic trial enrol would also note
conveni quick turnaround time liquid biopsi vs tissu base approach
could also help expedit enrol
identif novel gene target includ retrospect analysi sampl
translat applic uncov new drug target target discoveri
valid better understand mechan resist
companion diagnost develop includ pma submiss partner
support approv develop novel therapeut support add
addit gene exist approv
databas access guardant leverag grow databas patient profil
drive increment revenu biopharma partner
guardant offer panel biopharma partner
discuss previous guardant gene panel also detect
microsatellit instabl guardant ran test biopharma
partner asp forecast biopharma volum grow
year compound-annual-growth-rate therefor approxim test
gh second commerci product call guardantomni omni launch late
guardantomni liquid biopsi test design specif biopharma aid
acceler drug develop program io target therapi test
util learn input sever biopharma compani includ
merck azn bm omni assay includ gene encompass
known cancer pathway mani marker like largest
comprehens ctdna cancer gene panel avail today addit includ
gene panel omni detect homolog repair defici tumor
tumor mutat burden tmb provid quantit measur total number
mutat per code area serv predictor respons immunotherapi
agent recent bm demonstr tmb abl identifi nsclc patient
respond well combinatori immunotherapi phase front line clinic trial
import note omni sensit superior clinic action
biomark roughli similar variant addit specimen
requir low ml blood signific reduct
ml requir demonstr workflow improv guardant
abl make enhanc product believ lower sampl requir
make test even compel biopharma partner sampl
limit key gate factor
omni compris biopharma test volum asp
expect action omni panel increas new biomark becom
fda approv result model omni volum grow year compound-annual-growth-rate
approxim test wherea omni repres
biopharma test volum believ approxim biopharma test
volum dynam mark increas revenu consid
asp omni vs set
believ guardant biopharma collabor could support futur pma
submiss compani could seek fda approv omni pipelin
similar clinic set guardant test alreadi well adopt
biopharma commun guardant current work top pharma
biotech includ biopharma compani contract
johnson johnson bayer
guardant establish joint ventur jv amea inc softbank
may partnership form acceler commerci gh
product asia middl east africa near term focu japan depend
market opportun countri joint ventur may creat direct oper sell
distribut model licens third parti joint ventur dedic
fund current two larg studi underway japan lc-scrum-
japan scrum-japan gi-screen lung gastrointestin cancer use
test believ guardant gener jv revenu
grow respect adopt
guardant test grow outsid us
outsid jv guardant sold intern distributor total
countri gh sell thru distributor focu canada
latin america believ guardant gener non-jv intern
revenu forecast grow slightli
precis medicin yet meaning penetr recurr asymptomat
set part due fact infeas use tissue-bas test
serial monitor earli stage detect guardant launch lunar research
program may address need pipelin product program includ
detect cancer patient popul
detect cancer correctli guardant develop insight databas
omni test identifi posit neg genom indic
certain patient popul support develop product
compani work alongsid collabor variou academ institut
aim develop test residu diseas recurr detect
cancer survivor program initi focus lung colorect breast
ovarian cancer initi result indic guardant detect residu diseas
cancer patient relaps cours studi without prior knowledg
patient tumor signatur expect detect rate continu improv
compani knowledgebas increas process addit sampl compani
expect initi launch biopharmaceut partner research
use applic
although compani plan launch explicitli
incorpor revenu model revenu recognit pathway
remain unclear therefor revenu compani receiv would
repres upsid estim
target test earli detect cancer goal program
develop afford accur test potenti high complianc high
risk asymptomat individu exampl guardant investig ctdna
differenti earli cancer vs benign nodul lung cancer elig
patient could includ hereditari risk pre-exist infect
inflammatori condit
due earli result indic genom signatur alon may enough
reveal cancer patient popul guardant ad epigenom
chemic chang dna affect gene express biolog signatur
profil enhanc perform assay accord compani clinic
sensit test stage i-ii lung cancer stage i-ii
colorect cancer specif test across healthi
aged-match control
revenu forecast model consid launch
date reimburs landscap establish therefor would
repres upsid revenu estim
believ patient us stage iiib iv cancer metastat
need complex genet test assist therapi select believ mani
patient could insuffici tissu reason choos liquid
tissu biopsi asp rate guardant receiv
believ us clinic opportun guid therapi select
guardant abl receiv reimburs earlier stage cancer situat
tissu biopsi perform believ opportun could much
higher base annual cancer incid us believ guardant
roughli penetr lung opportun current cover criteria
penetr non-lung set
compani report cowen compani
guardant current sell countri outsid us distributor
jv softbank highli focus asia opportun countri
reimburs regulatori challeng navig clear
aggreg clinic opportun could sever multipl us
usincid growth stage iiib iv growth solid case distant cancer stage case distant cancer stage case distant cancer stage case distant cancer stage cancer insuffici case w/ distant solid cancer insuff non-solid case distant cancer stage case distant cancer stage opportun base late stage test perform cowen
believ market visibl lower biopharma revenu compar clinic
revenu varieti revenu stream potenti companion
diagnost deal biopharma opportun could much larger clinic
opportun today biopharma revenu size clinic revenu
contrast comprehens profil compani foundat medicin
biopharma revenu size clinic revenu
guardant offer servic biopharma custom includ prospect screen
identifi patient clinic trial immuno-oncolog program
opportun could approxim use
comprehens higher price omni test use addit guardant offer
partner omni test retrospect profil clinic trial sampl
uncov new insight respond vs non-respond group tumor evolut
resist biomark retest patient sampl would like larg
larger market prospect profil fact biopharma profil
guardant perform today retrospect analysi
guardant servic biopharma custom includ companion diagnost
develop databas access believ fda approv
compani expect end would make test compel biopharma
partner companion diagnost platform consid high sensit strong data
regulatori support conveni approach via liquid biopsi
guardant current databas patient sampl expect grow
significantli reach patient appli databas valu
project clinic biopharmaceut test sampl volum estim support
valu could argu would take valu
solid tumor survivor us believ mani could
candid screen test detect cancer recurr earli
clinician best chanc treat diseas asp repres
ten million asymptomat peopl us could elig
high risk cancer test depend high risk classifi high risk cohort could
includ heavi smoker sinc heavi smoke tobacco use link lung cancer
hereditari risk cancer current peopl
popul us smoke cigarett peopl popul
us smoke cigarett day addit popul thought
form hereditari diseas high proport diseas
oncolog two classifi alon elig popul could exceed
peopl annual test price market opportun
pleas find complet revenu model incom statement balanc sheet page
forecast clinic volum grow y/i driven recent
lcd lung cancer increas market awar test believ
cms/fda decis late caus inflect volum growth y/i
y/i overal clinic volum grow year compound-annual-growth-rate
forecast clinic grow y/i
driven recent lcd becam effect octob impli
medicar lung volum volum cover rate
also impli non-cm volum cover rate
believ continu improv assumpt
full year lcd lung reimburs rate non-
reimburs rate due privat payer adjust coverag polici
wake medicar lcd believ nation coverag decis
drive emb assumpt non-lung volum
reimburs rate non-cm reimburs rate improv
biopharma revenu build compos test revenu omni ivd/cdx
revenu revenu
biopharma test revenu forecast biopharma test revenu grow
y/i driven growth volum y/i growth asp
mix shift toward higher asp omni product believ volum
growth continu annual thereaft mix shift omni
drive asp growth y/i biopharma test revenu grow year
compound-annual-growth-rate approxim
ivd/cdx revenu forecast ivd/cdx revenu increas
materi assum cdx program
compani add one program year assum averag cdx
program contribut revenu year start
revenu revenu tie databas profil activ
clinic trial recruit current forecast revenu grow
believ compani high visibl
revenu stream due length custom contract forecast
revenu increas y/i respect
forecast gross margin improv
bump primarili driven clinic cog decreas
period expect cost save drive gross margin
respect area cost save includ autom
shift newer sequenc platform novaseq volum discount
forecast expens approxim y/i
reduct percentag sale y/i still doubl digit growth
believ compani need continu invest heavili drive
omni lunar product forward believ lunar program requir
multi-year invest therefor expens growth remain
y/i year
forecast expens sale grow
primarili due increas headcount cost associ
oper public compani
compani current peopl commerci team includ sale
rep rep target oncologist cancer center across
us impli current ratio oncologist sale rep forecast
 approxim y/i growth driven
assumpt compani need bolster sale forc effect reach
still expect sale rep larg territori cover cancer
diagnost space believ sale forc contact import essenti drive
order compani report approxim order physician may
place order without first visit sale repres addit
oncologist familiar improv like increas reorder rate
hope requir less salesforc contact fmi indic
volum came repeat order
cancer care us current occur commun set guardant
increasingli pursu commun opportun test volum
driven commun physician volum academ set
expect compani spend us drive awar new
product follow coverag forecast declin
percentag sale grow materi overal compani growth rate
valuat pt rational
share price gh trade ev/sal base forecast
premium high growth diagnost specialti lab peer group
median materi premium would note guardant year
revenu compound-annual-growth-rate strongli exce peer group mean
compani report thomson eikon cowen compani
follow key pillar price target
appli premium peer sale multipl project
test revenu forecast translat segment valu arguabl
higher premium could appli given growth outlook market
appli databas valu project clinic
biopharmaceut test sampl volum estim support valu
could argu would take valu pleas see
support databas valu methodolog next page
target price one would appli impli valuat
program lunar given compani strength
develop potenti market opportun associ
recurr monitor asymptomat screen believ
cowen compani
also note relev compar compani foundat medicin
acquir roch one-year forward sale
requir target price/shar invest current valu price target revenu valuetest volume-rel revenu group valuecumul volum option impli target mv less databas test valu cowen
june roch rhhbi outperform scala foundat medicin
enter definit merger agreement roch acquir outstand share
fmi common stock alreadi cash
translat valuat link cowen note
use similar framework one appli gh believ one
conclud roch valu fmi clinic databas roch
publicli indic acquisit motiv pharmaceut
develop aspir rel clinic test
cowen compani
februari roch announc plan acquir flatiron health link
flatiron health healthcar technolog compani oper oncologycloud
platform mani way flatiron next gener electron healthcar record
compani use softwar servic platform enabl commun clinician
provid better inform cancer care collect billion data point
million patient treat across network acceler biopharmaceut
research support evid gener
know mani live flatiron profil time deal knew
flatiron foundat medicin partner via partnership
collabor launch clinico-genom databas link clinico-genom
record design help research biopharmaceut partner acceler
develop target therapeut immunotherapi treat cancer
fmi assert hipaa-compli clinico-genom databas one largest
inform effort kind oncolog integr genom profil data
patient whose tumor sequenc assay togeth annot
longitudin clinic outcom data develop flatiron
revenu mm multiplevalu segment databasevalu per number patientsvalu databas total segment valu total databas valu total compani valu share count total compani valu per share cowen
januari geising regeneron form collabor perform whole
exom sequenc peopl geising health system make largest
clinic sequenc project undertaken thu far us project
sequenc first volunt abl confirm potenti gene
list target drug common medic condit includ high level
cholesterol triglycerid program sequenc individu
march regeneron glaxosmithklin announc plan uk biobank
contribut estim cost sequenc particip
biobank project initi invest fund sequenc sampl end
exchang fund gsk regeneron month exclus
data sequenc cost per sampl valu like higher even
month know exactli regeneron gsk agre fund
regardless view consist support analysi databas
also worth note time gsk/regn-uk biobank deal announc
gsk note target select new drug discoveri program
support human genet evid
loxo oncolog biopharma compani whose pipelin focus cancer
depend singl gene anomali compani creat drug treat
particular mutat regardless cancer type current compani sever
clinic trial underway basket studi patient type cancer
enrol long requir mutat oncolog patient trk-
estim patient harbor trk fusion-posit cancer
us annual advanc cancer larg enough
popul ration drug develop find patient prove elus
consid dearth broad genet test done upon cancer diagnosi
address problem foundationon provid loxo databas well-
genotyp oncolog patient loxo could identifi potenti studi particip
know much loxo paid access foundat medicin
databas provid access like greatli expedit recruit process still took
compani two year enrol patient although patient
would applic loxo drug us would still equat opportun
world-wide
privately-held lead consumer/person genet compani announc
januari enter agreement genentech gener whole
genom sequenc data approxim peopl parkinson
diseas commun result agreement announc januari genentech
abl access genom data peopl parkinson diseas
commun perform whole genom sequenc ultim goal
help genentech identifi new drug parkinson diseas provid addit
inform evid exist investig therapi genentech
pipelin compani said
accord forb genentech pay access data
patient whole genom sequenc per origin agreement worth
note genentech attract recruit
patient parkinson diseas genet phenotyp profil
assum genentech pay access patient data valu per
patient would
januari foundat medicin announc enter
collabor roch collabor includ equiti invest
certain govern provis collabor educ support
collabor ou commerci collabor bind term sheet
vitro diagnost product develop collabor
equiti invest includ primari invest roch cash
purchas newli issu share fmi common stock purchas price
per share tender offer roch acquir outstand share
fmi common stock price per share invest roch becam
fmi major sharehold septemb roch own approxim
fmi outstand common stock agreement roch buy
sell fmi share effort maintain agre upon ownership least
three year post transact close date april howev roch may pay
potenti five year access fmi molecular inform
platform fund product develop program also roch
minor represent seat fmi board director
total roch invest buy major stake fmi januari also
pledg time invest develop access fmi
databas drug develop purpos discuss roch manag
time made clear invest driven roch
pharmaceut also made clear time roch
belief roch saw primari valu fmi clinic test process
clinic diagnost revenu mean build proprietari databas
deepli genet sequenc cancer patient well-known phenotyp profil
roch evolv put valu clinic diagnost focu fmi
belief origin rational potenti use context establish valu
databas street project time roch invest
aggreg clinic pharmaceut test process use
roughli end roch standstil stipul invest agreement
suggest roch valu fmi per genet profil one could argu
actual closer per genet profil given roch arguabl
paid valu genet profil number test includ
process part biopharmaceut partnership valu per test
would far higher simpli use aggreg number test process
januari calcul
paid cash acquir decod genet iceland
individu genotyp decod time acquisit
suggest valu decod per genet profil note decod
posit strength time deal
decod found identifi human gene associ common
diseas via popul studi iceland one primari goal decod studi
use result drug develop purpos decod success
build databas success drug develop compani file
bankruptci went privat purchas
helmi eltoukhi ph ceo co-found dr eltoukhi serv chief
execut offic sinc januari prior found guardant dr eltoukhi held
variou posit august decemb includ senior
director advanc technolog research develop novel chemistri
hardwar informat genet analysi system june co-found
avantom inc commerci semiconductor sequenc help speed
democrat high throughput dna sequenc serv chief execut
offic acquisit august join stanford genom
technolog center sgtc post-doctor fellow work low-cost dna
sequenc technolog doctor studi sgtc develop
first semiconductor sequenc platform first base-cal algorithm next-
gener sequenc sever nation genom research institut
grant receiv ph degre electr engin
amirali talasaz ph presid dr talasaz serv presid
chief oper offic sinc januari prior found guardant dr talasaz held
variou posit includ senior director diagnost research
octob june led effort emerg clinic applic
next-gener genom analysi time develop differ genom
technolog suitabl clinic applic march found auriphex
bioscienc inc focus purif genet analysi circul tumor
cell cancer manag technolog acquir lllumina
academ year led technolog develop group sgtc receiv
ph degre electr engin degre electr engin
degre manag scienc engin stanford univers
derek bertocci cfo dr bertocci serv chief offic sinc juli
prior join guardant mr bertocci serv senior vice presid chief
financi offic achaogen inc februari decemb prior
mr bertocci senior vice presid chief offic
incorpor publicli trade radiat oncolog compani januari
septemb octob decemb mr bertocci serv
chief offic bioform medic inc publicli trade medic aesthet
compani june juli chief offic laserscop
publicli trade provid laser fiber optic devic urolog aesthet
surgeri prior mr bertocci spent number year variou role visx
incorpor publicli trade provid system laser vision correct surgeri
includ chief offic march may vice presid
control march mr bertocci hold degre
stanford univers degre univers southern california
mr bertocci also certifi public account inact
compani report cowen compani
mm except cagrcommentstot clinic revenu assumpt broader coverag improv aspsgrowth total includ sampl volum cdx milestones/revenu revenuegrowth total jv/ ou clinic jv japan other/miscellan growth note forecast us lunar revenu sourc total potenti cowen
compani report thomson eikon cowen compani
 develop oper salesnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmdepreci salesnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmoth income/expens interest count mm cowen
compani report cowen compani
mm except expens current current lt current lt lt paid deficit /retain liab sharehold cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk includ limit custom adopt could slower expect
reimburs clinic guidelin hurdl new competit gh trade
